{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:58:23Z","timestamp":1769605103621,"version":"3.49.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004374","name":"Chongqing Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004374","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.urolonc.2021.05.039","type":"journal-article","created":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T05:33:54Z","timestamp":1627450434000},"page":"743-753","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["The prognostic and clinicopathological significance of Tim-3 and PD-1 expression in the prognosis of upper urinary tract urothelial carcinoma"],"prefix":"10.1016","volume":"39","author":[{"given":"Han","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tonghui","family":"Weng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaobing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Gou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.urolonc.2021.05.039_bib0001","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.eururo.2020.05.042","article-title":"European association of urology guidelines on upper urinary tract urothelial carcinoma: 2020 update","volume":"79","author":"Roupr\u00eat","year":"2021","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2021.05.039_bib0002","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.eururo.2015.08.037","article-title":"Gender and bladder cancer: a collaborative review of etiology, biology, and utcomes","volume":"69","author":"Dobruch","year":"2016","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2021.05.039_bib0003","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/cas.12075","article-title":"Bacillus calmette-guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine","volume":"104","author":"Kawai","year":"2013","journal-title":"Cancer Sci"},{"issue":"2","key":"10.1016\/j.urolonc.2021.05.039_bib0004","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/path.5306","article-title":"Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches","volume":"249","author":"Song","year":"2019","journal-title":"J Pathol"},{"issue":"1","key":"10.1016\/j.urolonc.2021.05.039_bib0005","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00345-016-1835-1","article-title":"Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study","volume":"35","author":"Favaretto R","year":"2017","journal-title":"World J Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2021.05.039_bib0006","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.juro.2017.06.086","article-title":"Prognostic value of PD-1 and PD-L1 expression in patients with high grade upper tract urothelial carcinoma","volume":"198","author":"Krabbe L","year":"2017","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2021.05.039_bib0007","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.eururo.2012.02.030","article-title":"Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature","volume":"62","author":"Lughezzani","year":"2012","journal-title":"Eur Urol"},{"issue":"18","key":"10.1016\/j.urolonc.2021.05.039_bib0008","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1158\/1078-0432.CCR-12-1972","article-title":"Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy","volume":"19","author":"Nirschl","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.urolonc.2021.05.039_bib0009","doi-asserted-by":"crossref","first-page":"e30676","DOI":"10.1371\/journal.pone.0030676","article-title":"TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression","volume":"7","author":"Gao","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.urolonc.2021.05.039_bib0010","first-page":"1059","article-title":"Downregulated Tim-3 expression is responsible for the incidence and development of colorectal cancer","volume":"16","author":"Zhang","year":"2018","journal-title":"Oncol Lett"},{"key":"10.1016\/j.urolonc.2021.05.039_bib0011","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.3389\/fimmu.2019.01594","article-title":"The Tim-3-Galectin-9 pathway and its regulatory mechanisms in uman breast cancer","volume":"10","author":"Yasinska I","year":"2019","journal-title":"Front Immunol"},{"issue":"15","key":"10.1016\/j.urolonc.2021.05.039_bib0012","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1158\/1078-0432.CCR-18-4142","article-title":"Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non-small cell lung cancer using spatially resolved and multiparametric single-cell analysis","volume":"25","author":"Datar","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.urolonc.2021.05.039_bib0013","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13148-019-0752-8","article-title":"Molecular and immune correlates of TIM-3 (HAVCR2) and galectin 9 (LGALS9) mRNA expression and DNA methylation in melanoma","volume":"11","author":"Holderried","year":"2019","journal-title":"Clin Epigenetics"},{"key":"10.1016\/j.urolonc.2021.05.039_bib0014","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/978-3-319-15774-0_10","article-title":"Immune memory and exhaustion: clinically relevant lessons from the LCMV model","volume":"850","author":"Zehn","year":"2015","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"10.1016\/j.urolonc.2021.05.039_bib0015","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.eururo.2020.05.042","article-title":"European association of urology guidelines on upper urinary tract urothelial carcinoma: 2020 update","volume":"79","author":"Roupr\u00eat","year":"2021","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2021.05.039_bib0016","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/jso.24012","article-title":"T-cell immunoglobulin mucin-3 expression in bladder urothelial carcinoma: clinicopathologic correlations and association with survival","volume":"112","author":"Yang","year":"2015","journal-title":"J Surg Oncol"},{"issue":"9","key":"10.1016\/j.urolonc.2021.05.039_bib0017","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/art.38690","article-title":"Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome","volume":"66","author":"Fardet","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.urolonc.2021.05.039_bib0018","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12894-019-0457-5","article-title":"Prognosis and risk factors of patients with upper urinary tract urothelial carcinoma and postoperative recurrence of bladder cancer in central China","volume":"19","author":"Wang","year":"2019","journal-title":"BMC Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2021.05.039_bib0019","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1464-410X.2012.11068.x","article-title":"Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review","volume":"110","author":"Cutress","year":"2012","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.urolonc.2021.05.039_bib0020","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.juro.2016.03.194","article-title":"Upper urinary tract carcinoma in situ: current knowledge, future direction","volume":"197","author":"Redrow G","year":"2017","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2021.05.039_bib0021","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.eururo.2011.07.051","article-title":"Antegrade perfusion with bacillus Calmette-Gu\u00e9rin in patients with non-muscle-invasive urothelial carcinoma of the upper urinary tract: who may benefit?","volume":"60","author":"Giannarini","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2021.05.039_bib0022","doi-asserted-by":"crossref","first-page":"316","DOI":"10.12688\/f1000research.13446.1","article-title":"Immune regulation by Tim-3","volume":"7","author":"Banerjee","year":"2018","journal-title":"F1000Res"},{"issue":"1","key":"10.1016\/j.urolonc.2021.05.039_bib0023","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1261779","article-title":"Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer","volume":"6","author":"Shayan","year":"2017","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.urolonc.2021.05.039_bib0024","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1747333","article-title":"Identification and validation of poor prognosis immunoevasive subtype of muscle-invasive bladder cancer with tumor-infiltrating podoplanin(+) cell abundance","volume":"9","author":"Zhou","year":"2020","journal-title":"Oncoimmunology"},{"issue":"3","key":"10.1016\/j.urolonc.2021.05.039_bib0025","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1084\/jem.20090397","article-title":"Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion","volume":"207","author":"Huang","year":"2010","journal-title":"J Exp Med"},{"issue":"10","key":"10.1016\/j.urolonc.2021.05.039_bib0026","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1084\/jem.20100637","article-title":"Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients","volume":"207","author":"Fourcade","year":"2010","journal-title":"J Exp Med"},{"key":"10.1016\/j.urolonc.2021.05.039_bib0027","article-title":"Combined next-generation sequencing and flow cytometry analysis for an anti-PD-L1 partial responder over time: an exploration of mechanisms of PD-L1 activity and resistance in bladder cancer","author":"Kates","year":"2019","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2021.05.039_bib0028","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.eururo.2016.10.009","article-title":"Immunoregulation of dendritic cell subsets by inhibitory receptors in urothelial cancer","volume":"71","author":"Chevalier M","year":"2017","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2021.05.039_bib0029","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/CJI.0000000000000122","article-title":"Targeting PD-1 and Tim-3 pathways to reverse CD8 T-cell exhaustion and enhance ex vivo T-cell responses to autologous dendritic\/tumor vaccines","volume":"39","author":"Liu","year":"2016","journal-title":"J Immunother"},{"issue":"17","key":"10.1016\/j.urolonc.2021.05.039_bib0030","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1182\/blood-2010-10-310425","article-title":"Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia","volume":"117","author":"Zhou","year":"2011","journal-title":"Blood"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392100257X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392100257X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:21:31Z","timestamp":1761042091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107814392100257X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S107814392100257X"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.05.039","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The prognostic and clinicopathological significance of Tim-3 and PD-1 expression in the prognosis of upper urinary tract urothelial carcinoma","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.05.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}